Professional Documents
Culture Documents
Table 1. Hemoglobin (Hb) and Epistaxis Severity Score (EES) Values Before, 1 Month, and 2 Months During Therapy
Hb Hb Hb
Age of (Baseline) (After 1 Month) (After 2 Months) ESS ESS ESS
Patients Age Sex Onset Genotype gr/dL gr/dL gr/dL (Baseline) (Post-ADONA 1 Month) (Post-ADONA 2 Months)
Hb, hemoglobin; EES, epistaxis severity score; HHT, hereditary hemorrhagic teleangiectasia; Pat, patient; M: male; F: female.
efficacy for a new approach to management of epistaxis in 4. Dupuis-Girod S, Ambrun A, Decullier E, et al. ELLIPSE study: a
HHT. Phase 1 study evaluating the tolerance of bevacizumab nasal spray in
the treatment of epistaxis in hereditary hemorrhagic telangiectasia.
MAbs. 2014;6(3):794–799.
References 5. Zarrabeitia R, Albiñana V, Salcedo M, Señaris-Gonzalez B,
1. Shovlin CL. Hereditary hemorrhagic telangiectasia: pathophysio- Fernandez-Forcelledo JL, Botella LM. A review on clinical manage-
logy, diagnosis and treatment. Blood Rev. 2010;24(6):203–219. ment and pharmacological therapy on hereditary haemorrhagic
2. Sautter NB, Smith TL. Hereditary hemorrhagic telangiectasia-related telangiectasia (HHT). Curr Vasc Pharmacol. 2010;8(4): 473–481.
epistaxis: innovations in understanding and management. Int Forum 6. McLean WM, Campolongo JT. Carbazochrome salicylate as a
Allergy Rhinol. 2012;2(5):422–431. parenteral hemostat in tonsillectomy. Can J Surg. 1973;16(5):333–334.
3. Sabbà C, Gallitelli M, Palasciano G. Efficacy of unusually high doses 7. Hoag JB, Terry P, Mitchell S, Reh D, Merlo CA. An epistaxis
of tranexamic acid for the treatment of epistaxis in hereditary severity score for hereditary hemorrhagic telangiectasia. Laryngo-
hemorrhagic telangiectasia. N Engl J Med. 2001;345(12):926. scope. 2010;120(4):838–843.